Kennametal Inc. logo KMT - Kennametal Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 5
HOLD 13
SELL 5
STRONG
SELL 0
| PRICE TARGET: $37.10 DETAILS
HIGH: $47.50
LOW: $32.00
MEDIAN: $34.00
CONSENSUS: $37.10
UPSIDE: 7.88%

Stock News

Kennametal Unveils Next Level Shop Experience for IMTS 2026

Kennametal Unveils Next Level Shop Experience for IMTS 2026

Immersive booth brings live machining, industry experts, metal cutting innovations and a custom motorcycle build together under one roof PITTSBURGH, July 20, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) today announced it will bring the modern manufacturing ecosystem to life at IMTS 2026 with the Next Level Shop, an immersive experience featuring appearances of WIDIA brand ambassador Carey Hart, a live custom motorcycle build and the latest machining and digital manufacturing technologies designed to help manufacturers improve productivity. Building on the success of its Metal Mania experience two years ago, the Next Level Shop recreates the energy and collaboration of today's modern machine shop, bringing together tooling, software, machine tool builders and manufacturing experts to solve real-world production challenges.

Jul 20, 2026 06:00 AM • prnewswire.com
Kennametal Names Amanda Cole Vice President and Chief Human Resources Officer; Judith Bacchus to Retire after 20 years at the Company

Kennametal Names Amanda Cole Vice President and Chief Human Resources Officer; Judith Bacchus to Retire after 20 years at the Company

PITTSBURGH, June 30, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today the appointment of Amanda Cole as Vice President and Chief Human Resources Officer, effective July 21, 2026. Cole brings more than 20 years of experience in leading enterprise-wide transformation, cultural evolution and talent strategy, most recently serving as Vice President of Human Resources, Electrical & Electronic Solutions Business and IT & Digital Functions at Wesco International, Inc. She will succeed Judith Bacchus, who will retire on or about October 1, 2026, after more than 20 years at the company.

Jun 30, 2026 02:45 AM • prnewswire.com
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached –  – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj® (revumenib), decitabine/cedazuridine, and venetoclax in relapsed or refractory (R/R) NPM1 mutated (NPM1m), KMT2A-rearranged (KMT2Ar), or NUP98-rearranged (NUP98r) acute myeloid leukemia (AML) were published in the Journal of Clinical Oncology and simultaneously presented at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. Revuforj is the first and only menin inhibitor that is FDA approved for patients one year and older with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.

Jun 11, 2026 03:00 AM • globenewswire.com
Kennametal Strengthens Balance Sheet & Enhances Liquidity

Kennametal Strengthens Balance Sheet & Enhances Liquidity

Actions extend debt maturities, preserve financial flexibility and support growth opportunities Raised additional $700 million liquidity through new 3-year term loan and expansion of existing revolving credit facility Additional liquidity supports near-term tungsten related working capital needs while preserving long-term flexibility Refinanced $300 million in bonds, extending maturities to 2036, as previously reported Transactions consistent with maintained investment grade credit rating profile PITTSBURGH, May 29, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced a series of financing transactions designed to enhance liquidity, extend debt maturities and position the Company to capture near-term growth opportunities. The actions provide additional financial flexibility to support near-term tungsten related working capital needs while preserving flexibility to respond to future market developments.

May 29, 2026 04:30 AM • prnewswire.com
Kennametal Inc. Announces Final Results and Expiration of Cash Tender Offer for Debt Securities

Kennametal Inc. Announces Final Results and Expiration of Cash Tender Offer for Debt Securities

PITTSBURGH, May 27, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced the final results and expiration of its previously announced cash tender offer (the "Tender Offer") to purchase any and all of the outstanding notes listed in the table below (the "Notes"). Capitalized terms used in this news release and not defined herein have the meanings given to them in the Offer to Purchase, dated May 19, 2026 (the "Offer to Purchase").

May 27, 2026 02:45 AM • prnewswire.com
Kennametal Inc. Announces Pricing Terms of Cash Tender Offer for Debt Securities

Kennametal Inc. Announces Pricing Terms of Cash Tender Offer for Debt Securities

PITTSBURGH, May 26, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today announced the pricing terms of its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its outstanding 4.625% Senior Notes due 2028 (the "2028 Notes"). All other terms and conditions of the Tender Offer remain unchanged and are described in the Offer to Purchase, dated May 19, 2026 (the "Offer to Purchase").

May 26, 2026 11:25 AM • prnewswire.com
Kennametal to Attend KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference

Kennametal to Attend KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference

PITTSBURGH, May 18, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference in Boston. Details of the conference are as follows: When:   Wednesday, May 27, 2026   Attendees: Sanjay Chowbey, President and Chief Executive Officer Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.

May 18, 2026 09:00 AM • prnewswire.com

Price Targets